Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Feed Clear all
Completed Phase 2 Interventional Results available

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

NCT01711658
View directory record Official record
Conditions
Non-HPV Locally Advanced Head and Neck Cancer
Interventions
IMRT, Cisplatin, placebo, Lapatinib
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 29, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Bright Futures Oral Health Intervention

NCT01406366
View directory record Official record
Conditions
Health Knowledge, Attitudes, Practice
Interventions
Group 1: Bright Futures Oral Health Curriculum, Group 2: Iron Deficiency Training Module
Behavioral
Lead sponsor
Continuity Research Network
Network
Eligibility
12 Months to 35 Months
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 31, 2011 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Metabolic Consequences of CPT-1 Deficiency

NCT00653666
View directory record Official record
Conditions
Carnitine Palmitoyl Transferase Type 1A (CPT1A) Deficiency
Interventions
Medically supervised fasting
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Years to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Sep 29, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183
View directory record Official record
Conditions
Hearing Loss, Head and Neck Cancer
Interventions
Placebo, Atorvastatin
Other · Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 29, 2026, 6:42 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 29, 2026, 6:42 AM EDT
Completed No phase listed Observational

Enteral Feeding in the Post-Injury Open Abdomen

NCT01853735
View directory record Official record
Conditions
Trauma to the Abdomen
Interventions
Not listed
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 98 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 29, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

NCT04469530
View directory record Official record
Conditions
Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 29, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia

NCT06534359
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Gastroesophageal Reflux
Interventions
Transpyloric tube feeding, Gastric tube feeding
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery

NCT00497380
View directory record Official record
Conditions
Protein Metabolism
Interventions
Arginine
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Perioperative Nutritional Optimization in Head and Neck Cancer Patients

NCT04449445
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Isocaloric and iso-nitrogenous standard enteral tube feeds, Nestle IMPACT AR
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

NCT04067622
View directory record Official record
Conditions
Acute Respiratory Failure, Encephalopathy, ARDS, Sepsis, Critical Illness
Interventions
Exersides
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 29, 2026, 6:42 AM EDT
Not listed No phase listed Observational

Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation

NCT02995577
View directory record Official record
Conditions
Single Ventricle Physiology
Interventions
Feeding tolerant, Feeding intolerant, Necrotizing enterocolitis
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 3 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Desensitization to Reduce Oral Hypersensitivity and Improve Intake for Children With Feeding Disorders

NCT03739047
View directory record Official record
Conditions
Feeding Disorder
Interventions
Desensitization with flipped spoon, flipped spoon
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
10 Months to 10 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 29, 2026, 6:42 AM EDT
Completed No phase listed Observational

Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the Neonatal ICU (NICU)

NCT01666457
View directory record Official record
Conditions
Oral Feeding Outcomes, Growth, Length of NICU Stay
Interventions
SOFFI
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
3 Months to 5 Months
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

NCT01532518
View directory record Official record
Conditions
Colic
Interventions
Nepadutant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
Up to 6 Months
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

NCT02246218
View directory record Official record
Conditions
Urea Cycle Disorder
Interventions
RAVICTI
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Day to 2 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 29, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 29, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

NCT04335552
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of care, Hydroxychloroquine, Azithromycin
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Neonatal Release of Ankyloglossia

NCT00967915
View directory record Official record
Conditions
Ankyloglossia
Interventions
Frentomy, Sham procedure
Procedure · Other
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
0 Days to 14 Days
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Patterned Experience for Preterm Infants

NCT01577615
View directory record Official record
Conditions
Complication of Prematurity
Interventions
Patterned Experience
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 32 Weeks
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Sep 29, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 29, 2026, 6:42 AM EDT